Health and social care use, costs, and satisfaction among key workers accessing Resilience Hub support during the COVID-19 pandemic.

Publication date: Feb 04, 2025

Key workers are vulnerable to adverse mental health. To ensure service sustainability during COVID-19, Resilience Hubs were established across England offering outreach, screening, and mental health support. This evaluation aimed to describe wider service use, associated costs, and satisfaction among Hub clients (key workers) accessing Hub support. Clients accessing support across four Hubs were invited to complete a service use questionnaire, between 5 and 8 months post referral, collecting satisfaction, wider service use and cost data. Exploratory linear regression assessed the relationship between demographic variables and service use. Most Hub clients reported Hub contact post referral (219/299, 73. 2%), with many accessing mental health support (171/299, 57. 2%) or on waitlists (34/299, 11. 4%). Satisfaction was high, with median helpfulness rated 92 (out of 100), and many stating that Hubs either fully (148/299, 49. 5%) or partially (54/299, 18. 1%) met their needs. Mental health support accounted for most service use, with higher total service use and costs when including Hub services (lb514 versus lb213). Key workers have complex needs. Hub services helped clients to access support, with high reported satisfaction indicating that Hubs met clients needs. Further research is required to assess how service use varies according to occupation or demographic characteristics, and whether Hubs are clinically and cost-effective.

Open Access PDF

Concepts Keywords
Months Adult
Pandemic COVID-19
Sustainability COVID-19
Therapy England
Female
Healthcare service use
Humans
Key workers
Male
Mental health
Mental Health Services
Middle Aged
Pandemics
Patient Satisfaction
Resilience, Psychological
SARS-CoV-2
Service satisfaction
Surveys and Questionnaires

Semantics

Type Source Name
drug DRUGBANK Huperzine B
disease MESH COVID-19 pandemic
drug DRUGBANK Methionine
pathway REACTOME Reproduction
drug DRUGBANK Pentaerythritol tetranitrate
disease MESH emergency
drug DRUGBANK Etoperidone
disease MESH depression
disease MESH anxiety
disease MESH post traumatic stress disorder
disease MESH morbidity
drug DRUGBANK Coenzyme M
disease IDO site
disease MESH comorbidity
disease IDO intervention
drug DRUGBANK Trestolone
drug DRUGBANK Ethanol
disease MESH mental illness
disease IDO symptom
drug DRUGBANK Serine

Original Article

(Visited 3 times, 1 visits today)